Announcements Trials

Browse Landscape

Phase

Status

Unknown 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Hepatocellular 14 Carcinoma, Non-Small-Cell Lung 9 Colorectal Neoplasms 7 Stomach Neoplasms 6 Triple Negative Breast Neoplasms 5 Esophageal Squamous Cell Carcinoma 4 Cholangiocarcinoma 4 Uterine Cervical Neoplasms 3 Small Cell Lung Carcinoma 3 Pancreatic Neoplasms 3 Melanoma 3 Urinary Bladder Neoplasms 2 Recurrence 2 Rectal Neoplasms 2 Neoplasms 2 Nasopharyngeal Carcinoma 2 Lymphoma, Extranodal NK-T-Cell 2 Liver Neoplasms 2 Glioblastoma 2 Carcinoma, Transitional Cell 2 Breast Neoplasms 2 Advanced Biliary Tract Cancer 2 Urothelial Carcinoma Bladder 1 Urologic Neoplasms 1 Urogenital Neoplasms 1 Urinary Bladder Diseases 1 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Radiation Pneumonitis 1

Interventions

toripalimab 1 tislelizumab 1 liposomal doxorubicin 1 disitamab vedotin 1 RC48 antibody 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Muscle Invasive Bladder Cancer × tislelizumab × Clear all

NCT04813107 2022-02-22

ANTICIPATE

Jiangsu Yahong Meditech Co., Ltd aka Asieris

Phase 1/2 Unknown

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡